Vendor Sessions

MONDAY JUNE 20

0715–0815

1300–1400

1600–1700

TUESDAY JUNE 21

0715–0815

WEDNESDAY JUNE 22

0715–0815

Ammonia scavengers for Urea Cycle Disorder therapy
Monday June 20, 0715–0815

Presented by:
Medunik

Presenter: Murray Potter, McMaster University

Objective:

  • To describe the treatment of patients with urea cycle disorders particularly with pheburane (taste-masked granules of sodium phenylbutyrate).

Back to top

Skeletal Dysplasias: Identification of New Genes and Development of New Therapies
Monday June 20, 0715–0815

Presented by:
Alexion

Presenter: Philippe Campeau, Medical Geneticist, CHU Sainte-Justine Research Center, Assistant Clinical Professor, Department of Pediatrics, Université de Montréal

Objectives:

  • Overview of hypophosphatasia, presentation, differential diagnosis and case studies.
  • New treatment for hypophosphatasia.
  • The importance of diagnostic in hypophosphatasia.

Back to top

Laboratory Test Utilization-Opportunities, Strategies and leading change
Monday June 20, 1300–1400

Presented by:
Roche

Presenter: Amy Saenger, Mayo Clinic

Are you looking to improve Test Utilization?
Dr. Amy Saenger will talk about diagnostic costs, opportunities of improvement, strategies and how to lead change concerning laboratory test utilization.

Back to top

Natriuretic Peptides in diagnosis and therapeutic decision making in heart failure
Monday June 20, 1300–1400

Presented by:
Alere

Presenter: Alan Maisel, Professor of Medicine, Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System, UC San Diego

In this session you will learn the role of natriuretic peptides and the extension beyond heart failure diagnosis; it is a clinical support tool in risk stratification and management in both inpatient and outpatient settings which have become an essential part of medicine.

Back to top

Transforming Dry Technology
Monday June 20, 1300–1400

Presented by:
Ortho Clinical Diagnostics

Presenter: Marie-Claude Renaud, laboratory specialist manager and Helene Goulet, National Automation Specialist

Share some of the current and future programs that have created so much excitement at Ortho, and what this can mean to you and your laboratory – now and in the years to come. Overview of some of the projects that are making significant improvements to current products, that can help you with your current challenges. Note: a non-disclosure agreement (NDA) must be signed by all audience members before presenting this information.

Back to top

Advances in QC: A New, Robust Approach to Patient QC and Selecting Optimal Control Rules for PT/QC
Monday June 20, 1600–1700

Presented by:
ESBE

Presenter: George Cembrowski, Associate Professor in the Department of Laboratory Medicine and Pathology, University of Alberta

Presenter: Mark Cervinski, Assistant Professor of Pathology, Director of Clinical Chemistry, Director of Point-Of-Care Testing, Geisel School of Medicine, Dartmouth College

Two Salient topics will be covered. Dr. Cervinski will describe the optimal use of the very new Average of Deltas (AoD), in which intra-patient delas of tests are averaged to indicate clinically significant analytical shifts. The ease of computation of AoD and its sensitivity to bias will be covered. Dr. Cembrowski will discuss the control rules that should be used to identify random and systematic error in EQA results. Additionally, a new nomogram approach will be presented that easily provides the appropriate control rules to minimize the number of erroneous results in an analytical run.

Back to top

Fetal Scalp Lactate: An update on the BC experience
Monday June 20, 1600–1700

Presented by:
Nova Biomedical

Presenter: Li Wang,Clinical Assistant Professor, Dept of Pathology and Laboratory Medicine University of British Columbia Medical Biochemist BC Children’s Hospital

Objectives:

  • To review the evidence for using fetal scalp lactate to assess fetal acidemia.
  • To describe how fetal scalp lactate testing is performed and interpreted.
  • To share the experience and research findings using two different POCT lactate meters at BC Women’s Hospital.

Back to top

Are you missing anything? Improved Value of a High Density SNP and Copy Number Array for Constitutional and Cancer Applications
Tuesday June 21, 0715–0815

Presented by:
Affymetrix

Presenter: Jill Schurr,

The availability of advanced genetic assessment technologies enables cytogenetic researchers to identify significantly more copy number aberrations and other structural alterations associated with constitutional disorders and malignancies than ever before. Test methods such as karyotyping, fluorescent in situ hybridization (FISH), and low-resolution arrays have deficiencies in genomic coverage and limited resolution, thus reducing the number of significant variants that can be seen. Compromising on genomic coverage, content, or resolution leads to significant aberrations being missed, which necessitates further analysis, delaying results and increasing costs. Whole-genome microarrays that cover both polymorphic (SNPs) and non-polymorphic regions of the genome can be used to assess DNA copy number alterations at a much higher resolution than conventional cytogenetic analysis to support assessment of potentially causative genetic alterations such as DNA copy number variations (CNVs), chromosomal imbalances, and allele imbalance indicative of absence of heterozygosity (AOH), loss of heterozygosity (LOH), or long contiguous stretches of homozygosity (LCSH). The genetic complexity of cancer samples and their associated diagnostic and prognostic workflows require accurate high resolution detection of genome-wide aberrations in a mixed population of cells. This presentation will focus on the use of CytoScan® HD in constitutional and cancer applications. With superior gene coverage in a high density SNP array, peripheral blood samples can be assayed with confidence and convenience.

Back to top

Introducing BD Barricor™ – The next generation blood separation tube
Tuesday June 21, 0715–0815

Presented by:
BD

Presenter: Aparna Jha Ahuja,

Presenter: Denise Uetwiller,

Review of the next generation blood collection tube; BD Barricor™ including how it works, clinical data comparing to plasma and serum gel tubes and customer valve.

Back to top

Consumer Driven Point-of-Care – The Good, The Bad, and the Potential Impact on Laboratory Medicine
Tuesday June 21, 0715–0815

Presented by:
Siemens

Presenter: Jason Weshler,

Does the patient always know best? While the expansion of Point-of-Care Testing across Canada brings with it opportunities for improved chronic disease management, availability of information can also create further challenges within the healthcare system.

Today, new Point of Care initiatives are being piloted in various settings and for various tests – the regulations are slowly trying to catch-up. This session will explore some of the emerging trends, challenges with the dissemination of testing, and opportunities for increased laboratory engagement.

Back to top

Selecting the optimal genetic diagnostic strategy for my patient
Tuesday June 21, 0715–0815

Presented by:
Blueprint Genetics

Presenter: Tero Pekka Alastalo,

The talk will discuss the challenges presented in selecting genetic testing strategies with case examples used to illustrate how to optimize this process. Current strengths & weaknesses of different available technologies used in clinical genetic settings will also be discussed.

Back to top

Impact of next-generation sequencing on neurogenetic testing
Wednesday June 22, 0715–0815

Presented by:
Athena Diagnostics

Presenter: Susan Hahn,

Objectives:

  • Describe the impact of next-generation sequencing on genetic testing for neurogenetic conditions.
  • Discuss how enhanced exome sequencing can improve diagnosis of neurogenetic conditions.
  • Describe the application of responsible genomics.